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During differentiation, human embryonic stem cells
(hESCs) shut down the regulatory network conferring
pluripotency in a process we designated pluripo-
tent state dissolution (PSD). In a high-throughput
RNAi screen using an inclusive set of differentia-
tion conditions, we identify centrally important and
context-dependent processes regulating PSD in
hESCs, including histone acetylation, chromatin
remodeling, RNA splicing, and signaling pathways.
Strikingly, we detected a strong and specific enrich-
ment of cell-cycle genes involved in DNA replication
and G2 phase progression. Genetic and chemical
perturbation studies demonstrate that the S and
G2 phases attenuate PSD because they possess an
intrinsic propensity toward the pluripotent state
that is independent of G1 phase. Our data there-
fore functionally establish that pluripotency control
is hardwired to the cell-cycle machinery, where S
and G2 phase-specific pathways deterministically
restrict PSD, whereas the absence of such pathways
in G1 phase potentially permits the initiation of
differentiation.
INTRODUCTION
The human pluripotent stem cell state is facilitated by an intricate
regulatory network controlled chiefly by master transcription
factors (Boyer et al., 2005). These master regulators form
multiple regulatory connections with other transcription factors,
epigenetic modifiers, signal transduction pathways, non-coding
RNAs, and other regulators that, together, maintain self-renewal
and pluripotency (Ng and Surani, 2011; Young, 2011). Sus-
tenance of this internal regulatory network is dependent on
external cues from the cell culture environment. Human embry-
onic stem cells (hESCs)mainly rely on the basic fibroblast growth
factor (bFGF) and Activin/transforming growth factor b (TGF-b)564 Cell 162, 564–579, July 30, 2015 ª2015 Elsevier Inc.pathways for self-renewal (Beattie et al., 2005; Xu et al., 2005).
Withdrawal of these signaling pathways causes the shutdown
of the complex hESC regulatory network; we call this process
pluripotent state dissolution (PSD). Because many applications
of hESCs require their complete and efficient differentiation, it
is necessary to obtain detailed knowledge of how the hESC reg-
ulatory network is dissolved during differentiation. However,
because the maintenance of the pluripotent state requires multi-
ple interactions between regulatory pathways and factors, the
dissolution of such a state is likely to be an equally complex
process with multiple routes from which it can be enforced.
Although several studies have identified regulators of PSD in
mouse embryonic stem cells (mESCs) (Betschinger et al.,
2013; Guo et al., 2011), there is a lack of knowledge about how
PSD is regulated in hESCs.
Systematic studies like high-throughput functional genomics
assays have greatly advanced the knowledge about the regula-
tory networks of ESCs. The unbiased nature of functional geno-
mics makes it a powerful discovery tool for the identification
of key protein complexes and pathways by detecting multiple
crucial hits from the same pathway or complex. However, for
hESCs, most studies rely on expanding the hESC regulatory
network using previously known factors, and, to date, only one
arrayed high-throughput functional genomics study has been
performed in hESCs (Chia et al., 2010). Therefore, there is a
lack of knowledge in the molecular understanding of the regula-
tory network that governs PSD of hESCs.
To address this deficiency, we undertook a large-scale high-
throughput RNAi screen in differentiating hESCs for the de novo
identification of the molecular pathways regulating PSD. To be
comprehensive in dissecting PSD, we probed five differentiation
conditions to discover both context-dependent and universal
gatekeepers. Strikingly, we found a strong enrichment of cell-cy-
cle hits clustering specifically in S and G2 phases but not in other
phases of the cell cycle. Genetic and chemical manipulations of
cell-cycle progression established an intrinsic propensity toward
pluripotency maintenance in S and G2 phases, enacted by the
ataxia telangiectasia mutated (ATM)/ATR-mediated replication
checkpoint and Cyclin B1 pathways. Our study reveals a link
that hardwires the hESC pluripotency network to the cell-cycle
machinery, where S and G2 phase-specific pathways determin-
istically restrict PSD and the absence of such pathways at G1
phase could permit PSD.
RESULTS
A High-Throughput RNAi Screen under Multiple
Conditions Identifies Genes Important for PSD in hESCs
The process of ESC differentiation can be conceptually sub-
divided into two major steps: PSD, where the transcriptional
network of pluripotency is shut down, and lineage specification,
where a new transcriptional program corresponding to a specific
somatic lineage is assembled. Although the regulation of lineage
specification could differ greatly differ between different line-
ages, PSD is an early event for the ESC differentiation process.
To obtain evidence that PSD is distinct from lineage specifica-
tion, we looked at the expression kinetics of pluripotency and
lineage-specific genes upon withdrawal of the self-renewal fac-
tors bFGF and TGF-b. 48 hr after induction of differentiation, the
downregulation of many hESC-specific genes (Assou et al.,
2007) began (Figure S1A), but the upregulation of lineage-spe-
cific factor expression was only evident at 96 hr (Figure S1B).
An examination of gene expression of single cells showed similar
results (Figure S1C). Therefore, these data indicate that PSD oc-
curs immediately at the onset of differentiation, distinct from line-
age specification (Figure S1D). Because NANOG is decreased
significantly at both early and late time points (Figure S1A), we
assigned NANOG downregulation as a marker for PSD and
created a NANOG-GFP hESC line as a reporter of PSD (Figures
S1E–S1H).
To achieve robust and unbiased identification of universal
and specific factors required for PSD, we carried out a high-
throughput RNAi screen under five differentiation conditions
(Figure 1A). Under the first condition, we removed the two
important cytokines bFGF and TGF-b from hESC medium
(Beattie et al., 2005; Xu et al., 2005). Under the second to
fourth conditions, we individually perturbed signaling of the
TGF-b pathway as well as the mitogen-activated protein ki-
nase kinase (MEK) and phosphatidylinositol 3-kinase (PI3K)
branches of the bFGF pathway. Under the fifth condition, we
introduced retinoic acid (RA), a potent inducer of differentia-
tion. All conditions led to PSD, as indicated by the efficient
loss of hESC identity (Figures S1I–S1K). Cells were transfected
with siRNAs 24 hr before induction of differentiation. The de-
gree of preservation of hESC identity was then measured
through the average NANOG-GFP fluorescence intensity per
cell; hESCs depleted of PSD effectors are expected to retain
higher GFP signals. We screened a total of 4,558 genes in trip-
licate for all five conditions, summing up to 68,370 data points
(Table S1).
We first ensured the quality of the screen by checking for intra-
plate layout effects (Figure 1B; Figure S2A), proper inter-plate
alignment (Figure S2B), and good correlation between replicates
(Figure 1C; Figure S2C). Genes that reproducibly scored above
noise (z > 1.25 or z > 1.5 in at least two replicates) were regarded
as hits (Figure 1D). Hits obtained were observed to maintain a
visible GFP signal (Figure 1E). We detected no cell number
bias in hit selection (Figure S2D), eliminating the possibility thathousekeeping genes could be misidentified as hits. We further
conducted counter-screens using a hESC line harboring an
ACTIN-GFP reporter (Table S2) and found no overlap with the
NANOG-GFP hits (Figure S2E). Collectively, these results ascer-
tain that the RNAi screen identified genes important for PSD
rigorously and reliably.
Informatics Analyses Reveal Pathways that Regulate
PSD in a Context-Specific Manner
The screen was designed to enable the identification of both
context-dependent and universally important processes that
regulate PSD (Figure 2A). We examined the hits from the five
distinct conditions using protein interaction network (Figure 2B),
Reactome (Table S3), and gene ontology (Table S4) analyses to
look for context-dependent effectors of PSD.
First, we observed that the hits included factors that are asso-
ciated with the primary pathways transducing the distinct initial
differentiation cues. These include the repressors SKI and SKIL
for TGF-b inhibition (Figure 2B), the ERK2 inactivator DUSP6
for MEK inhibition (Table S1), and the RA receptor RXRA and
the transcriptional complexes RNA polymerase II and transcrip-
tion factor II D (TFIID)/Mediator for +RA (Figure 2B; Table S1).
This is reassuring because perturbation of these primary path-
ways is expected to nullify the differentiation-inducing effect
stemming from the same pathway, demonstrating the robust-
ness of the high-throughput screening assay.
Interestingly, the RNA splicing machinery seems to play a role
in PSD, especially during RA addition andMEK inhibition (Tables
S3 and S4). This is notable because, although multiple RNA
splicing factors have been reported to control the pluripotent
state of hESCs (Gabut et al., 2011; Lu et al., 2013), it has been
unknownwhether they also regulate its dissolution. RNA splicing
has been shown in other cell types to interact with the MEK and
RA pathways (Shilo et al., 2014;Wang et al., 2015). Similar mech-
anisms might be in place in hESCs, explaining why RNA splicing
could affect PSD triggered specifically by MEK inhibition or RA
introduction. Our study therefore opens the door for studying
the crosstalk between the splicing machinery, PSD, and these
developmental pathways.
Besides RNA splicing, studying the functional genetics of PSD
further revealed novel nodes of contact between signaling path-
ways and pluripotency. For example, we observed an enrich-
ment of nucleosome-remodeling deacetylase (NuRD) complex
members under conditions where bFGF-MEK signaling is
abolished (Figure 2B; Table S4). The NuRD complex has an
established role in promoting PSD in mESCs (Kaji et al., 2006;
Reynolds et al., 2012), and our results demonstrate the conser-
vation of this function in hESCs. Interestingly, although the
leukemia inhibitory factor (LIF)-Stat3 pathway opposes the
action of the NuRD complex in mESCs (Hu and Wade, 2012),
this role seems to be assumed by the bFGF-MEK pathway in
hESCs. On the other hand, a strong enrichment of histone
demethylases, specifically those targeting histone 3 lysine 4
(H3K4), was observed under the PI3K pathway inhibition condi-
tion (Figure 2B; Tables S3 and S4). This points toward an epige-
netic link between the PI3K pathway and the pluripotency
network through the maintenance of activating H3K4 methyl-
ation marks.Cell 162, 564–579, July 30, 2015 ª2015 Elsevier Inc. 565
Figure 1. A High-Throughput RNAi Screen for Regulators of PSD
(A) Schematic of the siRNA screen. siNT, non-targeting siRNA; siOCT4, siRNA against POU5F1 (OCT4); siGFP, siRNA against GFP.
(B) Representative plate heatmap from the bFGF, TGF-b condition.
(C) Scatterplot showing the correlation between screen replicates under the bFGF, TGF-b condition.
(D) Representative dot plot of the results of the transcription factor and epigenetic modifier subset from thebFGF,TGF-b condition. The gray line indicates the
cutoff Z score (>1.5).
(E) Representative images forNANOG-GFP fluorescence (green) and Hoechst staining (blue) for hits under the five differentiation conditions. Scale bars, 200 mm.
See also Figures S1 and S2 and Tables S1 and S2.Finally, we noticed that developmental pathways play highly
context-dependent roles in PSD. For instance, Wnt signaling-
associated factors, particularly those regulating b-catenin-
mediated transcription, were enriched in hits during inactive566 Cell 162, 564–579, July 30, 2015 ª2015 Elsevier Inc.bFGF-MEK signaling (Figure 2B; Tables S3 and S4). This is in
agreement with the identified cross-regulation between these
two pathways (Ding et al., 2005; Singh et al., 2012) and the
pro-differentiation role of nuclear b-catenin in hESCs (Davidson
(legend on next page)
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et al., 2012; Dravid et al., 2005). On the other hand, negative
regulators of the PI3K pathway are enriched under the bFGF,
TGFb condition (Table S3), whereas positive regulators are
enriched under the +RA condition (Figure 2B; Table S3). The
PI3K pathway therefore seems to help uphold pluripotency in
hESCs (Figures S1I–S1K) in coordination with both the bFGF
and TGFb pathways (Singh et al., 2012) but promotes differenti-
ation instead when acting downstream of RA. These results
emphasize the importance of studying the role of developmental
pathways in the proper context.
Therefore, separate analyses of the various screening condi-
tions demonstrate the robustness of our screen results in addi-
tion to identifying context-dependent processes that are crucial
for PSD.
Combined Analysis Uncovers Epigenetic Mechanisms
that Universally Regulate PSD upon Withdrawal of Self-
Renewal Signals
Hierarchical clustering of the results from the five conditions
revealed that the +RA condition is excluded from a tight clus-
ter comprising the other four conditions (Figure 2C). This was
conceivable given that the +RA condition introduces a differen-
tiation signal in contrast to the withdrawal of self-renewal signals
under the other four conditions. Therefore, we next performed a
combined analysis of the four clustering conditions (Figures 2D–
2F) to find central pathways that are important for PSD induced
by the removal of self-renewal signals.
The combined analysis identified members of multiple
chromatin-modifying complexes important for PSD. Histone
acetyltransferase (HAT) complex proteins appear to be top hits
(Figures 2D–2F), most prominently those that belong to Spt-
Ada-Gcn5-acetyltransferase (SAGA)-type (TATA-binding pro-
tein-free TAF-containing complex [TFTC]/SPT3-TAF9-GCN5-
acetylase complex [STAGA]) and TIP60 (NuA4) HAT complexes.
Strikingly, the catalytic subunit of the TIP60 complex KAT5 is
among the top five hits of all four conditions (Table S1), underlin-
ing the importance of this complex in PSD. Although histone
acetylation levels are known to be higher in undifferentiated
ESCs (Legartova´ et al., 2014), a global but transient increase in
histone acetylation occurs during PSD (Golob et al., 2008),
potentially necessitating the activity of HAT complexes at the
onset of PSD. Nucleosome remodeling is also essential because
knockdown of multiple Switch/sucrose non-fermentable (SWI/
SNF) family members prevented efficient downregulation of
NANOG in differentiating hESCs (Figures 2D and 2F). Notably,
certain members of these complexes, such as Trrap of the
NuA4 complex and Arid1a of the SWI/SNF complex, have a
conserved function in shutting down pluripotency in ground-Figure 2. Identification of Context-Dependent and Universally Importa
(A) Diagram outlining the major findings from the RNAi screen.
(B) Protein-protein interaction networks of genes that are uniquely enriched fo
conditions under which the gene was identified as a hit. See also Tables S3 and
(C) Heatmap depicting hierarchical clustering by Euclidian distance between diff
(D) Enriched gene clusters from the protein-protein interaction network analysis
whereas the node color indicates the degree of integration (number of edges) of
(E) Overrepresented pathways (p < 0.05) from the combined hits as determined
(F) Representative terms (p < 0.05) for enriched functional annotation clusters fro
568 Cell 162, 564–579, July 30, 2015 ª2015 Elsevier Inc.state mESCs (Betschinger et al., 2013). Therefore, our study
systematically highlights the importance of epigenetic regula-
tions in the PSD of hESCs.
The Cell-Cycle Machinery Deterministically Regulates
PSD
Besides epigenetic modifiers, our combined analysis also re-
vealed that genes involved in cell-cycle regulation were among
the most enriched (Figures 2D–2F), particularly those that are
involved in DNA replication during S phase or in G2-to-M transi-
tion (Figures 2D and 2E). On the contrary, we found no strong
enrichment of processes specific to other phases of the cell
cycle, implying that specific cell-cycle regulations influence the
cell fate transitions of pluripotent cells. Although the cell cycle
has been found to influence cell fate decisions in perspectives
other than proliferation (Lee et al., 2014; Rodier et al., 2009),
knowledge about the regulation of PSD by the cell cycle is
limited, especially for G1-independent cell-cycle states such
as S and G2 phases. To explore this topic, we first functionally
validated the effect of cell-cycle genes in PSD by impeding
DNA replication or prolonging the gap phases using both genetic
and chemical approaches (Figure 3A).
Genetic validation of the S- and G2-associated hits confirmed
that their depletion (Figures S3A and S3B) impedes pluripotency
gene downregulation after removal of self-renewal signals (Fig-
ures 3B and 3C). Because their depletion concomitantly perturbs
progression through the cell cycle (Figures S3C and S3D), these
results suggest that extending the S and G2 phases of the hES
cell cycle may dominantly impede PSD. In contrast, although
lengthening of G1 phase is associated with differentiation, artifi-
cially extending G1 phase by knocking down CDK4/6, depleting
Cyclin D, or overexpressing the CDK inhibitor p21 (Figures S3E–
S3G) did not significantly affect the downregulation of pluripo-
tency markers upon removal of self-renewal signals (Figure 3D).
These findings suggest that the lengthening of G1 phase does
not elicit a deterministic effect on PSD of hESCs. NANOG-GFP
fluorescence was also preserved (Figure S3H), and differentia-
tion marker upregulation was inhibited (Figures S3I–S3K) upon
knockdown of S and G2 phase progression genes but not
upon G1 phase prolongation, corresponding with the observed
changes in pluripotency marker expression.
Because depletion of cell-cycle-related hits impeded S and
G2 phase progression, we next validated whether direct manip-
ulation of these cell-cycle phases using chemical inhibitors can
similarly affect PSD.With proper dosage, wemanaged to enrich,
but not completely arrest, hESCs in specific cell-cycle phases
(Figure S4A) without inducing extensive apoptosis (Figures
S4B and S4C). In concordance with our screen results, we foundnt Regulators of PSD
r the different screening conditions. The node color indicates the screening
S4.
erent screening conditions.
of the combined hits. The node size indicates the average Z score of the hits,
the gene with the entire network of hits.
using the web resource Reactome.
m the combined hits.
Figure 3. Deterministic Regulation of the Cell Cycle on PSD
(A) Schematic outlining the cell-cycle perturbations at specific phases.
(B–E) qPCR for pluripotency genes upon genetic perturbations of (B) DNA replication, (C) G2 phase progression, and (D) G1 phase progression or upon
(E) treatment with small molecules enriching for specific cell-cycle phases under the bFGF, TGF-b condition. Triplicate data are represented as mean ± SD.
(F) Images for embryoid bodies and immunofluorescence staining of differentiated cells derived from H1 hESCs treated with various cell-cycle inhibitors under
the bFGF, TGF-b condition. N.A., no cells survived. Scale bars, 100 mm.
See also Figures S3 and S4.
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Figure 4. The Propensity for Promoting Pluripotency in S and G2 Phases Is Intrinsic and G1 Phase Independent
(A) Boxplots depicting time spent in G1 and S/G2 phases as calculated using live cell imaging of FUCCI H1 hESCs after various cell-cycle perturbations. *p < 0.05
compared with empty vector or DMSO control.
(B) Diagram depicting the difference in lengths of time-controlled and cell-cycle number-controlled experiments.
(legend continued on next page)
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that perturbing DNA replication in S phase as well as delaying
mitotic transition from G2 phase consistently deterred PSD in
different hESC lines (Figure 3E; Figures S4D–S4G). In contrast,
inhibitors that led to an elongation of G1 and M phases did not
exhibit PSD attenuation (Figure 3E; Figures S4D–S4G), proving
that restriction of PSD is not conferred by simply locking cell-cy-
cle progression. Importantly, these observed changes in marker
expression ultimately influenced the functional pluripotency of
hESCs (Figure 3F).
Because cell-cycle manipulations in ESCs inevitably lead to a
certain degree of cell death (Ruiz et al., 2011; Figures S4B and
S4C), wewanted to ascertain that the effects of cell-cycle pertur-
bation on PSD are not just a secondary effect of cell death. We
observed that the levels of induced cell death did not correlate
with the effects of cell-cycle perturbation on PSD (Figure S4H).
Additionally, inhibition of apoptosis during perturbation of S or
G2 phase did not alter the observed delay in PSD (Figure S4I).
These findings collectively indicate that the effects of cell-cycle
perturbation on PSD are independent of cell death.
Together, these data demonstrate that the cell cycle can
dominantly influence PSD. More importantly, these results also
indicate that resistance to PSD is potentially mediated by spe-
cific cell-cycle events in S and G2 phases.
The Propensity of S and G2 Phases toward Pluripotent
State Maintenance Is Intrinsic and G1 Phase
Independent
G1 phase of the cell cycle has been correlated to susceptibility to
differentiation, attributed to a higher expression of differentiation
markers (Singh et al., 2013) and the enrichment of cell-cycle fac-
tors like cyclin-dependent kinase (CDK) inhibitors and G1 cyclins
that contribute to lineage specification (Li et al., 2012; Pauklin
and Vallier, 2013). Because the reduction in proportion of cells
in G1 phase was observed when we delayed progression in
the S and G2 phases (Figures S3C and S3D and S4A), it can
be argued that the resulting PSD block could be an indirect effect
of an inaccessibility to G1 phase or G1-associated factors that
initiate differentiation.
To test this hypothesis, we first measured the actual time cells
spend in G1 and S/G2 phases using the fluorescent ubiquitina-
tion-based cell-cycle indicator (FUCCI) reporter (Sakaue-Sa-
wano et al., 2008). Although hESCs spent more time in S/G2
phase when we interfered with DNA replication and G2 phase
progression, the absolute time in G1 phase remained largely un-
changed (Figure 4A). However, the collective time spent in G1
phase was still decreased when we allowed the cells to differen-
tiate for the same period of time (Figure 4B). Therefore, we
measured pluripotency marker expression after an equal num-
ber of cell divisions in untreated and cell-cycle-perturbed hESCs
(Figure 4C). In these experiments, we observed that PSDwas still
attenuated in hESCs with delayed S or G2 phase progression
(Figure 4C), ruling out the possibility that the restriction of PSD
could be a result of G1 phase inaccessibility.(C) qPCR for pluripotency genes under thebFGF,TGFb condition upon cell-cy
cell cycles. Triplicate data are represented as mean ± SD.
(D) Western blot for p21, p27, and Cyclin D1 levels upon knockdown of S and G
(E) qPCR for nascent transcripts of pluripotency genes collected from H1 hESCsWe next checked whether the expression levels of G1
phase-specific factors that are implicated in differentiation
were decreased. Neither CDK inhibitors, such as p21 and p27,
nor Cyclin D were downregulated upon knockdown of S or G2
phase-related hits (Figure 4D). In fact, the protein levels of these
G1-associated factors were increased slightly, indicating that
the consequent prevention of PSD is definitely not due to an
unavailability of G1-associated lineage specification factors.
Because delayed PSD could not be explained via the length of
G1 phase or by its associated factors, this phenomenon might
stem from a direct effect of S- and G2-specific pathways, which
render these phases of the cell cycle intrinsically inclined toward
pluripotent state maintenance.
We also examined the transcription of pluripotency factors
to look for potential cell-cycle phase-specific regulation. The
steady-state levels of pluripotency genes have been found pre-
viously to remain similar across the hESC cycle (Singh et al.,
2013). However, when we examined de novo transcription levels
of pluripotency regulators in different cell-cycle phases, genes
such as NANOG and PRDM14 were preferentially transcribed
during S and G2/M phases compared with G1 phase (Figure 4E).
This suggests that the S and G2 phases may be intrinsically
wired into maintaining pluripotency, therefore delaying PSD
when progression through these cell-cycle phases is altered.
Activation of the ATM/ATR-Mediated Checkpoint at S
Phase Attenuates PSD
To look for the specific cell-cycle machineries that uphold the
pluripotency network, we first checked pathways that are acti-
vated when S phase is perturbed. Perturbation of DNA replica-
tion generates replication stress, which can lead to DNA damage
accumulation and subsequent activation of the ATM/ATR-medi-
ated checkpoint (Bakkenist and Kastan, 2003; Zou and Elledge,
2003). Indeed, we observed elevated gH2AX foci (Figure S5A)
and CHEK1/2 phosphorylation (Figure 5A; Figure S5B) after
perturbation of DNA replication. To test whether this activation of
the checkpoint is causative for blocking PSD, we subdued ATM/
ATR-mediated checkpoint signaling in hESCs using various
checkpoint inhibitors (Figure 5B). Genetic and chemical inhibi-
tion of the sensor kinases ATM and ATR or of the effector kinase
CHEK2 reversed the block on PSD by aphidicolin, as evidenced
by the downregulation of pluripotency markers (Figures 5C and
5D; Figures S5C–S5F). These changes in gene expression trans-
late to functional pluripotency, as observed in teratoma forma-
tion assays (Figure 5E). In addition, inhibition of the checkpoint
similarly abolished the PSD delay resulting from knockdown of
replication-associated hits (Figure 5F). These results from both
genetic and chemical approaches demonstrate that signaling
through the ATM/ATR-CHEK2 axis directly contributes to plurip-
otency. Interestingly, in all cases where the checkpoint activated
by aphidicolin treatment was abolished, DNA replication re-
mained largely delayed (Figure 5G). This verifies that the PSD
block is not a result of a simple S phase lock or the physical statecle perturbations, with data collection time points normalized to the number of
2 phase-associated hits.
sorted into different cell-cycle phases according to DNA content.
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Figure 5. ATM/ATR-CHEK2 Prevents PSD upon Replication Arrest
(A) Western blot of phosphorylated CHEK2 and CHEK1 proteins upon treatment with cell-cycle inhibitors.
(B) Outline of manipulations performed on the ATM/ATR pathway.
(C andD) qPCR for pluripotency genes under thebFGF,TGFb condition upon treatmentwith aphidicolin concomitantwith (C) treatmentwith short hairpin RNAs
(shRNAs) against ATM/ATR pathway members or (D) inhibition of the ATM/ATR pathway with small molecules. Triplicate data are represented as mean ± SD.
(E) Table describing teratoma formation efficiencies of H1 hESCs treated with aphidicolin, AZD7762, and caffeine under the bFGF, TGFb condition, and
teratoma formation assay for aphidicolin-treated cells.
(legend continued on next page)
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of DNA during replication but a direct result of ATM/ATR-medi-
ated checkpoint activation. Finally, activation of the ATM/ATR
pathway byDNA damage-inducing reagents similarly attenuated
PSD (Figure 5H; Figure S5G), confirming that checkpoint activa-
tion can directly block PSD.
The activity of the ATM/ATR pathway on PSD is specifically
downstream of the S phase replication perturbation because
increased CHEK2 phosphorylation was not observed when
perturbing other cell-cycle phases (Figure S5H). Besides, inhib-
iting checkpoint signaling did not change PSD kinetics when per-
turbing the other cell-cycle phases (Figure S5I). Interestingly, we
observed higher activity of the ATM/ATR pathway in unperturbed
hESCs in S phase compared with other cell-cycle phases (Fig-
ure 5I), suggesting that this pathway may also contribute to the
intrinsic propensity of S phase toward pluripotent state mainte-
nance. In summary, these results demonstrate the ATM/ATR-
mediated checkpoint is the dominant PSD inhibitor downstream
of DNA replication perturbation and, likely, also during normal S
phase progression.
The ATM/ATR-Mediated Checkpoint Activates p53 to
Enhance TGF-b Signaling and Uphold Pluripotency
To obtain a mechanistic connection between ATM/ATR-CHEK2
activation and pluripotent state retention in hESCs, we per-
formed a time course microarray analysis in hESCs treated
with the DNA replication inhibitor aphidicolin and the checkpoint
inhibitor AZD7762 (Figure 6A). Upon aphidicolin treatment, we
observed an upregulation of genes involved in active TGF-b
signaling and a simultaneous downregulation of BMP4 pathway
genes and TGF-b pathway antagonists (Figures 6B and 6C;
Figures S6A and S6B). The changes in TGF-b pathway gene
expression led to enhanced TGF-b signaling, as indicated by
increased SMAD2 phosphorylation (Figure 6D; Figure S6C),
and can be mimicked by knockdown of replication-related
hits (Figure 6E; Figure S6D). Importantly, the augmentation of
TGF-b signaling can be reversed by checkpoint inhibitor treat-
ment (Figures 6B–6D; Figure S6E), confirming that the effect
on TGF-b signaling is directly from checkpoint activation. These
results therefore establish that the ATM/ATR-CHEK2 axis aug-
ments TGF-b signaling.
The TGF-b pathway has a well-known role in promoting the
human pluripotent state (James et al., 2005), which we observed
to occur in a dose-dependent manner (Figure S6F). Therefore, it
can be inferred that heightened TGF-b signaling is responsible
for PSD inhibition during replication perturbation. However, it
is also possible that the block in PSD occurs upstream of
the changes in TGF-b-related gene expression. We therefore
compared time course expression profiles upon the with-
drawal of self-renewal signals and observed that TGF-b-related
gene expression changes occur earlier and to a greater degree(F) qPCR for pluripotency genes upon knockdown of S phase-associated hits tog
Triplicate data are represented as mean ± SD.
(G) Fluorescence-activated cell sorting (FACS) quantification of Hoechst staining i
hESC medium.
(H) qPCR for pluripotency genes under the bFGF, TGFb condition upon treat
mean ± SD.
(I) Western blot for phosphorylated CHEK2 levels in H1 hESCs sorted according
See also Figure S5.compared with pluripotency marker expression changes (Fig-
ure 6C). This implies that the changes in TGF-b-related gene
expression are under closer control of the ATM/ATR-mediated
checkpoint compared with pluripotency genes. In addition,
these changes were detected even when cells were in hESCme-
dium (Figure S6E), and altered TGF-b-related expression does
not simply correlate with pluripotency status (Figure S6G). These
data rule out the possibility that changes in TGF-b-related gene
expression could be a secondary effect from delayed PSD and
support the notion that pluripotent state preservation occurs
as a result of the initial augmentation of TGF-b signaling.
Changes in TGF-b-related gene expression upon check-
point activation indicate an underlying transcriptional regulatory
mechanism. To find out the responsible transcription factor, we
first looked at the canonical transcription factor p53 because it is
activated by the ATM/ATR-CHEK2 axis during DNA damage
response in S phase (Banin et al., 1998; Hirao et al., 2000; Tib-
betts et al., 1999; Figure 6D; Figures S6C, S6D, and S6H) and
was observed to have binding sites near TGF-b-related genes
in hESCs (Akdemir et al., 2014). We therefore manipulated p53
levels in hESCs to observe its effect on the prevention of PSD
by checkpoint activation (Figure 6F). TP53 knockdown (Fig-
ure S6I) in checkpoint-activated hESCs not only abolished the
delay in PSD (Figure 6G) but also reversed the altered expres-
sion of TGF-b-related genes (Figure 6H), proving its necessity
in impeding PSD. Moreover, stabilization of p53 without DNA
damage using Nutlin-3 (Figures S6J and S6K) is sufficient to
delay pluripotency marker downregulation (Figure 6I) and alter
TGF-b-related gene expression (Figure 6J) in the absence of
self-renewal factors. Importantly, Nutlin-3 treatment did not
induce significant changes in cell-cycle profile of hESCs (Fig-
ure S6L), confirming that p53 can directly delay PSD indepen-
dent of cell-cycle changes. These data demonstrate both the
necessity and sufficiency of p53 in upholding the human plurip-
otent state. Finally, in line with the elevated ATM/ATR activity
during S phase (Figure 5I), we observed higher p53 protein and
SMAD2 phosphorylation levels in S phase-sorted hESCs (Fig-
ure S6M), implying that the mechanisms discussed work simi-
larly during normal progression through the cell cycle.
Collectively, our data strongly argue for a detailed mechanism
behind how S phase perturbation upholds pluripotency (Fig-
ure 6K). In the presence of replication stress or DNA damage,
p53 stabilization by ATM/ATR-CHEK2 signaling enhances
TGF-b pathway signaling, which consequently sustains NANOG
expression (Vallier et al., 2009; Xu et al., 2008) and preserves the
pluripotent state.
High Levels of Cyclin B1 in G2 Phase Attenuate PSD
We finally looked at how the enrichment of hESCs at G2 phase
could delay PSD (Figure 7A). Genetic and chemical perturbationsether with DMSO or AZD7762 treatment under the bFGF, TGFb condition.
ndicating the cell-cycle status of H1 hESCs after ATM/ATR pathway inhibition in
ment with DNA damage-inducing reagents. Triplicate data are represented as
to cell-cycle phases based on DNA content.
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of G2 phase progression resulted in a consistent elevation of Cy-
clin B1 expression (Figure 7B; Figure S7A), but not other cyclins
(Figure 7B). Furthermore, Cyclin B1 was higher in hESCs sorted
inG2 phase (Figure S7B). Therefore, we hypothesized that Cyclin
B1 might be the underlying cause for promoting the pluripotent
state during G2 phase. Interestingly, when we knocked down
Cyclin B1 in hESCs (Figure S7C), a dramatic downregulation of
pluripotency marker expression was observed prior to cell death
(Figure 7C; Figure S7D), indicating a tight linkage between Cyclin
B1 and pluripotency. Cyclin B1 knockdown enriched cells in G2
phase instead of G1 phase (Figure 7D), strikingly demonstrating
a decoupling of the expected cell-cycle profile associated
with differentiation. We furthermore overexpressed Cyclin B1 in
hESCs (Figure S7E) and demonstrated that overexpression of a
single cell-cycle factor can delay PSD (Figure 7E; Figure S7F).
Moreover, Cyclin B1 overexpression did not cause a significant
enrichment of cells in G2 phase (Figure 7F), indicating that Cy-
clin B1 prevents PSD downstream of G2 phase prolongation.
Importantly, these observations extend to protein levels of plu-
ripotency markers (Figure S7G), are replicable in other hESC
lines (Figures S7H and S7I), and, ultimately, affect functional
pluripotency (Figure 7G). Together, these results indicate that
Cyclin B1 is a connecting node between G2 phase and its abil-
ity to prevent PSD. To investigate how Cyclin B1 promotes the
pluripotent state, we performed a time course microarray anal-
ysis of hESCs overexpressing Cyclin B1. Interestingly, we also
found an initial upregulation of TGF-b agonists (Figures S7J and
S7K), suggesting that Cyclin B1 might also work through TGF-b
to prevent PSD.
DISCUSSION
The Context-Dependent Regulation of PSD
Differentiation necessitates the disintegration of the pluripo-
tency network. However, how differentiation cues lead to the
breakdown of this network is ill-defined, especially in hESCs.
To identify genes required for PSD, we performed a systematic
large-scale RNAi screen under multiple conditions to examine
the regulation of PSD given various cues initiating differentia-
tion. First, we observed that the regulation of PSD upon RA
introduction is starkly divergent from the conditions under which
hESCs were deprived of self-renewal signals (Figure 2C). This
implies that the effectors of PSD vary when self-renewal signals
are withdrawn versus when a differentiation signal is introduced
and that the mode of differentiation induction influences PSDFigure 6. Augmentation of the TGF-b and p53 Pathways by the ATM/A
(A) Schematic of the time course microarray experiment.
(B) Microarray heatmap for differentially expressed genes upon treatment with a
(C) Time course qPCR for pluripotency and TGF-b-related genes upon treatment
data are represented as mean ± SD.
(D) Western blot of phospho-SMAD2 and p53 proteins upon treatment of H1 hES
(E) qPCR for TGF-b agonists (color) and antagonists (grayscale) under the bFG
(F) Outline of experimental manipulations performed on the ATM/ATR-CHEK2-p
(G–J) qPCR of H1 hESCs under the bFGF, TGF-b condition for (G) pluripot
knockdown of TP53 concomitant with treatment with aphidicolin or (I) pluripot
stabilization of p53 with Nutlin-3. Triplicate data are represented as mean ± SD.
(K) Schematic outlining the mechanism behind the regulation of pluripotency by
See also Figure S6.regulation. Second, our multi-conditional screening approach
identified both general and context-specific regulators of PSD.
We found that the withdrawal of self-renewal signals is asso-
ciated with several common PSD effectors. Members of chro-
matin-modifying complexes such as HAT complexes and the
SWI/SNF complex were highly enriched, emphasizing a univer-
sal need to restructure the chromatin to enable complete cell
fate transition during PSD (Figures 2D–2F). Conversely, other
PSD regulators, like RNA splicing and Wnt signaling, tend to
function in a more context-dependent manner (Figure 2B).
Finally, we found that multiple members of certain complexes
play a role in PSD (Figures 2B and 2D), providing a starting point
to sift out the function of different members of protein com-
plexes by revealing the ones which are specifically important
for PSD in hESCs. Together, our large-scale RNAi study pro-
vides a unique resource for dissecting the mechanisms behind
PSD by providing new insights into the universal roles of various
factors and pathways on PSD while raising important notions
about the inherent context specificity of the regulatory network
governing PSD in hESCs.
The Deterministic Effect of Cell-Cycle States on PSD
During proliferation, cells experience dramatic biochemical and
physical changes by going through the cell cycle. This results
in distinct cell-cycle states, which cells have evolved to utilize
to prime and regulate other events that are not immediately
related to proliferation, such as immune response, metabolism,
and lineage specification (Lee et al., 2014; Pauklin and Vallier,
2013; Rodier et al., 2009). Despite increasing evidence showing
that the cell cycle regulates other cellular processes, there is no
direct or functional evidence that cell-cycle states can control
the pluripotency network and its dissolution. Here we demon-
strate that specific cell-cycle states dominantly block PSD in
hESCs. Specifically, when progression through the S or G2
phases of the hES cell cycle is perturbed, cells are enriched at
specific cell-cycle states withmachineries that trigger a selective
preference toward pluripotency maintenance and delay PSD
(Figure 3). Particularly, the ATM/ATR-CHEK2-mediated activa-
tion of p53 and Cyclin B1 upregulation during arrest at the S
and G2 phases, respectively, defines their respective cell-cycle
states and exerts control over the pluripotency network. More-
over, these pathways are not only activated at the perturbed
states but are also involved in natural cell-cycle progression (Fig-
ure 5I; Figures S6M and S7B). Therefore, these pathways and
their effects in upholding pluripotency can be applied to normalTR-Mediated Checkpoint
phidicolin and AZD7762 under the bFGF, TGFb condition.
with aphidicolin and AZD7762 under the bFGF, TGFb condition. Triplicate
Cs with aphidicolin and AZD7762.
F, TGF-b condition upon knockdown of replication-related genes.
53 axis.
ency genes and (H) TGF-b agonists (color) and antagonists (grayscale) upon
ency genes and (J) TGF-b agonists (color) and antagonists (grayscale) upon
the ATM/ATR-mediated checkpoint.
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progression through S and G2 phases. Overall, our investigation
provides the first evidence that cell-cycle machineries corre-
sponding to specific states can directly and dominantly regulate
the human pluripotent state.
Furthermore, the employment of the said pathways by the
S andG2 phases establish their active role in boosting the plurip-
otent state. This differs from the current perspective that the
S and G2 phases passively retain the pluripotent state given
that only G1 phase harbors a propensity to receive extracellular
differentiation signals and express lineage-specific factors
(Scott et al., 1982; Singh et al., 2013). In fact, we hypothesize
that the absence of such pathways in G1 phase may underlie
its responsiveness to differentiation cues. Therefore, we propose
that the S/G2 and G1 phases shift the weights between pluripo-
tency maintenance and PSD priming across the hES cell cycle
(Figure 7H). This model advocates that a balance between cell-
cycle phases is critical for ESC fate determination, unlike the
previously recognized G1-centric model.
Consequences of Fate Choices upon DNA Damage in
Pluripotent Stem Cells
During proliferation, stem cells can encounter various situations,
like replication stress, DNA damage, and checkpoint activation.
How stem cells make their fate choices in response to these spe-
cial but prevalent cell-cycle events has direct consequences on
genome stability, tissue development, and stem cell mainte-
nance. Here we demonstrate that pluripotent stem cells resist
cell fate changes in the presence of replication-induced DNA
damage (Figure 5). We further show that the DNA damage-
induced checkpoint stabilizes p53 to regulate TGF-b pathway
gene expression and retain pluripotency marker expression
(Figure 6). As a hub transcription factor, p53 is known to enact
diverse functions under different cellular contexts and activation
dynamics (Aylon and Oren, 2007; Chang et al., 2011; Ubil et al.,
2014). Although p53 activation has been thought to trigger
apoptosis or differentiation in hESCs (Qin et al., 2007), chromatin
bindingofp53differsdependingonwhether it is activatedbyadif-
ferentiation signal or DNAdamage (Akdemir et al., 2014). Herewe
demonstrate a new perspective where p53 acts to maintain the
human pluripotent state upon the withdrawal of self-renewal fac-
tors (Figures 6F–6J). By retaining the pluripotent cell fate in the
face of DNA damage, cells benefit from an increased efficiency
of DNA damage repair because ESCs are known to express
higher levels of homologous recombination and damage repairFigure 7. Cyclin B1 Attenuates PSD upon G2 Phase Prolongation
(A) Outline of manipulations performed on Cyclin B1.
(B) Western blot of cyclin levels upon knockdown of G2-associated hits.
(C) qPCR for pluripotency genes upon knockdown of Cyclin B1 in hESC medium
(D) FACS quantification indicating the cell-cycle status of H1 hESCs based on D
(E) qPCR for pluripotency genes under the bFGF, TGF-b condition upon over
(F) FACS quantification indicating the cell-cycle status of H1 hESCs based on D
(G) Images for embryoid bodies and immunofluorescence staining of differentiat
TGF-b condition. Scale bars, 100 mm. See also Figure S7.
(H) Model for the deterministic regulation of the cell cycle on PSD. The G2 and S
pluripotent state-promoting pathways.
(I) Summary of the findings from the high-throughput RNAi screen for PSD. Both co
model of PSD regulation in hESCs. The color scheme for core gatekeepers follows
Figure 2B.proteins (Momcilovic et al., 2010; Tichy et al., 2010). Furthermore,
if the damage incurred is beyond the capacity to repair, then
hESCs have the choice to undergo apoptosis more effectively
because of a lower apoptotic threshold in hESCs compared
with differentiated cells (Dumitru et al., 2012; Liu et al., 2013). As
a result, pluripotent stem cells can more efficiently resolve dam-
age before committing to differentiation or, if the damage is
beyond repair, terminate themselves to avoid the potential detri-
mentof giving rise to lineageprogenitorswithdamagedgenomes.
Conclusions
In conclusion, our systematic functional screening of hESCs
under multiple differentiation conditions enabled the identifica-
tion of both universal and specific gatekeepers for PSD (Fig-
ure 7I). We unravel a universal regulatory role for HAT complexes
and the SWI/SNF complex in PSD, whereas the NuRD complex,
RNA splicing, and signaling pathways regulate PSD in a context-
specific manner. Our screen unexpectedly discovered a strong
enrichment of cell-cycle hits clustering specifically in S and G2
phases but not in other phases of the cell cycle. Our mechanistic
studies demonstrate that the S and G2 phases possess an
intrinsic propensity toward the pluripotent state, mediated by
the ATM/ATR-CHEK2-p53 and Cyclin B1 pathways, respec-
tively. Therefore, we introduce a new paradigm for the coupling
of cell cycle and pluripotency in which the S and G2 phases
employ pathways that inhibit PSD and maintain ESC identity,
whereas the absence of such pathways in the G1 and M phases
potentially contributes to their amenability to PSD (Figure 7H).
EXPERIMENTAL PROCEDURES
Cell Culture
The hESC lines H1 (WA-01), HES2, HES3, NANOG-GFP H1 reporter, and
ACTIN-GFP H1 reporter were used for this study. They were cultured feeder-
free onMatrigel (BD Biosciences) with mTeSR1medium (STEMCELL Technol-
ogies). Themediumwas changed daily. The hESCswere routinely subcultured
with 1 U/ml Dispase in DMEM/F12 (STEMCELL Technologies) every 4–5 days.
For experiments, hESCs were passaged using TrypLE Express (Life Technolo-
gies) before treatment. See Supplemental Experimental Procedures for exper-
imental treatment protocols.
High-Throughput RNAi Screening
Pooled small interfering RNAs (siRNAs) (2.5 ml of 1 mM; Dharmacon, Ambion)
were printed on 384-well plates (Greiner) coated with 303-diluted Matrigel
(BD Biosciences) and frozen at 80C before use. Lipofectamine RNAi Max
(Invitrogen) diluted 2003 in 5 ml OptiMEM (Invitrogen) was added per well. Triplicate data are represented as mean ± SD.
NA content after Cyclin B1 knockdown in hESC medium.
expression of Cyclin B1. Triplicate data are represented as mean ± SD.
NA content after Cyclin B1 overexpression in hESC medium.
ed cells derived from H1 hESCs overexpressing Cyclin B1 under the bFGF,
phases are inclined toward pluripotent state maintenance because of active
re and context-specific gatekeepers were uncovered, providing amechanistic
Figure 2D, whereas the color scheme for context-specific gatekeepers follows
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and incubated at room temperature for 20 min. 3,000 NANOG-GFP H1 hESCs
in 45 ml mTeSR1 (STEMCELL Technologies) were seeded into each well. 24 hr
after seeding, mTeSR1 was replaced with the following differentiation media:
bFGF,TGF-b condition (mTeSR1without select growth factors [STEMCELL
Technologies]), TGF-b pathway inhibition (mTeSR + 1 mM A8301 [Stemole-
cule]), MEK pathway inhibition (mTeSR1 + 2.5 mM PD0325901 [Sigma]), PI3K
pathway inhibition (mTeSR1 + 20 mM LY294002 [STEMCELL Technologies]),
and +RA (mTeSR1 + 20 mMRA [Sigma]). Cells were incubated in differentiation
media for 120 hr for condition 1 and 48 hr for conditions 2–5. Media were then
replaced with mTeSR1 and incubated for another 24 hr. Cells were then fixed
with 4% paraformaldehyde (Sigma) and stained with Hoechst 3342 (1:4,000,
Invitrogen). Microscope images were acquired using ImageXpress Ultra
(Research Instruments) at 203magnification and quantified usingMetaXpress
image acquisition and analysis software. See Supplemental Experimental Pro-
cedures for informatics analysis.
qRT-PCR
RNAextractionusingTRIzol (Invitrogen), reverse transcriptionusingSuperscript
II (Invitrogen), andqPCRusingSYBRGreen (KAPA)were all performed via stan-
dard procedures. Measured transcripts were normalized to GAPDH levels.
Immunoblotting and Immunostaining
Immunoblotting and immunostaining were performed as conventional proce-
dures. See Supplemental Experimental Procedures for details and antibodies
used.
Microarray
mRNAs derived from hESCs were reverse-transcribed, labeled, and analyzed
on an Illumina microarray platform (HumanHT-12 v4 Expression BeadChips)
according to the manufacturer’s instructions. Rank invariant normalization
was applied.
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